Related Experiment Videos

US EPA signals renewed regulatory scrutiny of toxic air pollution

The Lancet. Respiratory Medicine

|February 24, 2022

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial.

The Lancet. Respiratory medicine·2026

Duration of effectiveness of tuberculosis preventive treatment across various tuberculosis burden settings: a systematic review and individual-participant meta-analysis.

The Lancet. Respiratory medicine·2026

State-level burden of chronic respiratory diseases in the USA, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Respiratory medicine·2026

Accuracy of type 2 inflammatory biomarkers to diagnose asthma in adults and children: a meta-analysis of 30 studies with prospective validation in an adult primary care cohort.

The Lancet. Respiratory medicine·2026

Risk factors for hospital admission and mortality in patients with influenza virus infection: a systematic review and meta-analysis.

The Lancet. Respiratory medicine·2026

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 2-5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study.

The Lancet. Respiratory medicine·2026

See all related articles